You are viewing the site in preview mode
Skip to main content
|
Characteristics
|
No. of estimates
|
Meta-RR estimate (95%CI)
|
I2 test (%)
|
p-value
|
Egger’s test
|
|---|
|
ML
|
|
Overall
|
7
|
1.56 (1.10–2.20)
|
45.06
|
0.0114
|
0.0063**
|
|
High exposure
|
4
|
1.28 (0.87–1.88)
|
40.98
|
0.2051
|
0.0984
|
|
Low exposure
|
1
|
2.24 (0.65–7.71)
|
NA
|
0.2012
|
NA
|
|
Any exposure
|
2
|
2.15 (1.29–3.58)
|
0.00
|
0.0033
|
NA
|
|
Study type
|
|
Case-control studies
|
0
| | | |
NA
|
|
Cohort studies
|
7
|
1.56 (1.10–2.20)
|
45.06
|
0.0114
|
0.0063**
|
|
AML
|
|
Overall
|
27
|
1.30 (1.09–1.55)
|
48.91
|
0.0037
|
0.0155**
|
|
High exposure
|
8
|
1.65 (1.13–2.41)
|
46.97
|
0.0100
|
0.1176
|
|
Low exposure
|
5
|
1.54 (0.89–2.66)
|
58.71
|
0.1248
|
0.2679
|
|
Any exposure
|
14
|
1.14 (0.93–1.39)
|
36.29
|
0.2057
|
0.3933
|
|
Study type
|
|
Case-control studies
|
9
|
1.34 (1.03–1.75)
|
40.12
|
0.0281
|
0.5929
|
|
Cohort studies
|
18
|
1.29 (1.02–1.63)
|
51.98
|
0.0364
|
0.0119**
|
|
CML
|
|
Overall
|
18
|
1.25 (1.00–1.55)
|
0.00
|
0.0456
|
0.2347
|
|
High exposure
|
3
|
2.79 (1.44–5.40)
|
0.00
|
0.0024
|
0.7110
|
|
Low exposure
|
2
|
1.93 (0.64–5.82)
|
0.00
|
0.2447
|
NA
|
|
Any exposure
|
13
|
1.11 (0.87–1.40)
|
0.00
|
0.4019
|
0.4132
|
|
Study type
|
|
Case-control studies
|
5
|
1.93 (1.05–3.56)
|
25.76
|
0.0353
|
0.6999
|
|
Cohort studies
|
13
|
1.13 (0.89–1.45)
|
0.00
|
0.3215
|
0.3540
|
|
MDS
|
|
Overall
|
9
|
1.87 (1.39–2.52)
|
40.73
|
< 0.0001
|
0.0560
|
|
High exposure
|
6
|
1.80 (1.18–2.75)
|
51.97
|
0.0065
|
0.1173
|
|
Low exposure
|
2
|
2.29 (1.51–3.48)
|
0.00
|
< 0.0001
|
NA
|
|
Any exposure
|
1
|
1.64 (0.83–3.22)
|
N/A
|
0.1510
|
NA
|
|
Study type
|
|
Case-control studies
|
5
|
1.85 (1.28–2.67)
|
33.43
|
0.0012
|
0.5538
|
|
Cohort studies
|
4
|
1.94 (1.19–3.18)
|
43.78
|
0.0081
|
0.1088
|
- *MPN not included as only one published point estimate was identified.**statistically significant (p. < 0.05)
